Vor Biopharma Inc. (VOR)

Vor Biopharma Statistics

Total Valuation

Vor Biopharma has a market cap or net worth of $877.81 million. The enterprise value is $442.40 million.

Market Cap	877.81M
Enterprise Value	442.40M

Important Dates

The next estimated earnings date is Wednesday, May 13, 2026, after market close.

Earnings Date	May 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Vor Biopharma has 54.19 million shares outstanding. The number of shares has increased by 187.35% in one year.

Current Share Class	54.19M
Shares Outstanding	54.19M
Shares Change (YoY)	+187.35%
Shares Change (QoQ)	+203.75%
Owned by Insiders (%)	2.19%
Owned by Institutions (%)	34.29%
Float	38.31M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 18.20

Current Ratio	18.20
Quick Ratio	18.08
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-70.41%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-77.90%
Weighted Average Cost of Capital (WACC)	14.78%
Revenue Per Employee	n/a
Profits Per Employee	-$4.52M
Employee Count	154
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +50.36% in the last 52 weeks. The beta is 1.92, so Vor Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.92
52-Week Price Change	+50.36%
50-Day Moving Average	14.29
200-Day Moving Average	24.03
Relative Strength Index (RSI)	56.62
Average Volume (20 Days)	1,328,193

Short Selling Information

The latest short interest is 3.42 million, so 6.30% of the outstanding shares have been sold short.

Short Interest	3.42M
Short Previous Month	3.39M
Short % of Shares Out	6.30%
Short % of Float	8.92%
Short Ratio (days to cover)	5.44

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-341.94M
Pretax Income	-695.98M
Net Income	-695.98M
EBITDA	-339.05M
EBIT	-341.94M
Earnings Per Share (EPS)	-$70.50

Balance Sheet

The company has $455.21 million in cash and $3.00 million in debt, with a net cash position of $452.21 million or $8.35 per share.

Cash & Cash Equivalents	455.21M
Total Debt	3.00M
Net Cash	452.21M
Net Cash Per Share	$8.35
Equity (Book Value)	-164.31M
Book Value Per Share	-4.24
Working Capital	432.93M

Cash Flow

In the last 12 months, operating cash flow was -$142.71 million and capital expenditures -$941,000, giving a free cash flow of -$143.65 million.

Operating Cash Flow	-142.71M
Capital Expenditures	-941,000
Depreciation & Amortization	2.89M
Net Borrowing	n/a
Free Cash Flow	-143.65M
FCF Per Share	-$2.65

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Vor Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-187.35%
Shareholder Yield	-187.35%
Earnings Yield	-77.80%
FCF Yield	-16.06%

Analyst Forecast

The average price target for Vor Biopharma is $45.44, which is 180.49% higher than the current price. The consensus rating is "Buy".

Price Target	$45.44
Price Target Difference	180.49%
Analyst Consensus	Buy
Analyst Count	10
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 19, 2025. It was a reverse split with a ratio of 1:20.

Last Split Date	Sep 19, 2025
Split Type	Reverse
Split Ratio	1:20

Scores

Altman Z-Score	n/a
Piotroski F-Score	2